Should You Buy Nike Stock Before the Huge Investor Update? | NKE STock Analysis
Summary
Parkev argues that Nike (NKE) stock, despite a 29% year-to-date decline, is still overvalued due to significantly worsened fundamentals. He previously warned investors about Nike's overvaluation given the headwinds, and while the price has fallen, the underlying business issues persist.
The company's revenue remains flat at $11.3 billion, a 3% decline on a currency-neutral basis, which is a significant reversal from its historical high single-digit growth rates. Nike's new CEO, Elliott Hill, has shifted strategy to rebuild relationships with wholesalers after the previous direct-to-consumer approach backfired. While wholesale revenues are showing early signs of recovery, up 1% currency-neutral, this comes at the expense of Nike's direct-to-consumer business, which saw digital sales down 9% and store sales down 5%. Parkev notes that clear signs of a successful turnaround strategy are lacking, with progress being very slow.
Other concerns include inventory management, with Parkev observing widespread discounts on Nike shoes, even premium Jordan brand products, despite the company's stated goal of selling at full price and becoming a more premium brand. This suggests an oversupply of core products. Furthermore, sales in Greater China, a crucial growth market, were down 7% in the most recent quarter and 11% over nine months, contrasting sharply with competitors like Lululemon, which are experiencing over 20% growth in the region. Profit margins are also declining, with gross profit margins falling by 130 basis points to 40.2% and EBIT margin dropping to 5.6% in the recent quarter, attributed partly to increasing tariffs and trade barriers.
Parkev calculates a fair value for Nike at $36.21. Given the current market price of approximately $45, he believes the stock is overvalued. He advises against buying Nike stock before the earnings announcement, stating he would not purchase it at current prices with the existing prospects. He is waiting for either significant improvement in the company's outlook or a further decline in its stock price before considering an investment.
Mentioned Stocks
Reasoning: Parkev maintains a negative outlook on Nike (NKE) stock, despite a 29% year-to-date decline, because he believes the fundamentals have worsened to such a degree that the current market price of $45 still makes it overvalued. He calculates a fair value for Nike at $36.21. His reasoning stems from several factors: revenue is flat (down 3% currency-neutral), wholesale recovery is slow (up 1% currency-neutral) at the expense of direct-to-consumer sales (digital down 9%, stores down 5%), indicating a lack of clear success for the new strategy. He also notes significant discounting of Nike products, including Jordan brand, contrary to the company's premium branding efforts, suggesting inventory issues. Sales in Greater China are a major concern, having fallen 7% in the quarter and 11% over nine months, while competitors like Lululemon are seeing strong growth in the region. Furthermore, profit margins are under pressure, with gross margins down 130 basis points and EBIT margin falling to 5.6% due to factors like increased tariffs. Given these persistent headwinds and the overvaluation, Parkev advises investors "not to buy" the stock before earnings, stating he would like to own it but "not at these prices with these prospects."